March 3, 2020
Takeda Pharmaceutical said on March 2 that it has received the thumbs-up from a key European panel for approval of its ALK inhibitor Alunbrig (brigatinib) for the first-line treatment of ALK-positive non-small cell lung cancer (NSCLC). The European Medicines Agency’s...read more